- Home
- CIFR vs HCM Comparison
CIFR vs HCM Comparison
Compare CIFR & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- HCM
- Stock Information
- Founded
- CIFR 2021
- HCM 2000
- Country
- CIFR United States
- HCM Hong Kong
- Employees
- CIFR N/A
- HCM N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- HCM Health Care
- Exchange
- CIFR Nasdaq
- HCM Nasdaq
- Market Cap
- CIFR 1.9B
- HCM 2.3B
- IPO Year
- CIFR N/A
- HCM N/A
- Fundamental
- Price
- CIFR $5.49
- HCM $16.11
- Analyst Decision
- CIFR Strong Buy
- HCM Hold
- Analyst Count
- CIFR 10
- HCM 1
- Target Price
- CIFR $7.83
- HCM $19.00
- AVG Volume (30 Days)
- CIFR 13.7M
- HCM 71.4K
- Earning Date
- CIFR 02-25-2025
- HCM 03-19-2025
- Dividend Yield
- CIFR N/A
- HCM N/A
- EPS Growth
- CIFR N/A
- HCM N/A
- EPS
- CIFR N/A
- HCM N/A
- Revenue
- CIFR $152,466,000.00
- HCM $610,806,000.00
- Revenue This Year
- CIFR $20.12
- HCM N/A
- Revenue Next Year
- CIFR $123.56
- HCM $15.89
- P/E Ratio
- CIFR N/A
- HCM N/A
- Revenue Growth
- CIFR 76.34
- HCM N/A
- 52 Week Low
- CIFR $2.66
- HCM $12.84
- 52 Week High
- CIFR $7.99
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- CIFR 46.95
- HCM 68.69
- Support Level
- CIFR $5.85
- HCM $13.58
- Resistance Level
- CIFR $6.33
- HCM $13.96
- Average True Range (ATR)
- CIFR 0.48
- HCM 0.31
- MACD
- CIFR 0.01
- HCM 0.34
- Stochastic Oscillator
- CIFR 27.82
- HCM 89.84
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.